Treatment of the dyslipidemia of insulin resistance.
The increase in ischemic cardiovascular mortality and morbidity in persons with insulin resistance has been adequately documented elsewhere in this issue. Some of the most important risk factors for this increased mortality and morbidity are the lipid abnormalities, which form two out of five criteria for defining the metabolic syndrome, a definition focusing on risk factors for ischemic cardiovascular disease. This article explores the description, pathophysiology, and treatment of these atherogenic lipid abnormalities.
Smith
Donald A
DA
Zena and Michael A. Wiener Cardiovascular Institute, Marie-Josee and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, Box 1014, 1 Gustave Levy Place, New York City, NY 10029-657, USA. donald.smith@mssm.edu
D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood*; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D007328:Insulin; D008055:Lipids